Thyroid Treatment: A Doctor's Guide for 2026

Why Thyroid Disease Is Fundamentally a Women's Health Issue

Thyroid disease is not equally distributed. Women account for approximately 75% of all thyroid disorder diagnoses, and the reasons are rooted in sex-specific immune biology, estrogen's effect on thyroid-binding globulin, and the repeated hormonal shifts of the female reproductive lifespan.

Your thyroid, a butterfly-shaped gland at the base of your neck, produces two hormones: thyroxine (T4) and triiodothyronine (T3). These regulate metabolism, heart rate, body temperature, mood, and fertility. When output is too low (hypothyroidism) or too high (hyperthyroidism), nearly every system in your body feels it.

Why Hormones Complicate the Picture for Women

Estrogen raises levels of thyroid-binding globulin (TBG), the protein that carries thyroid hormones in the blood. This means total T4 and T3 levels rise during pregnancy and when taking estrogen-containing contraceptives, which can make standard lab ranges misleading if your clinician is not interpreting them in context.

Progesterone has a mild competing effect, and the natural estrogen decline of perimenopause shifts thyroid hormone dynamics again. A TSH that was stable for years can drift out of range in your 40s without any change in diet or medication.

The Autoimmune Factor

The most common cause of hypothyroidism in the developed world is Hashimoto's thyroiditis, an autoimmune condition in which your immune system attacks thyroid tissue. Women develop Hashimoto's at roughly 10 times the rate of men. The immune shifts of the postpartum period, in particular, trigger a condition called postpartum thyroiditis in 5-10% of women, which can swing from hyperthyroid to hypothyroid and back within the first year after delivery.

Understanding Your Diagnosis: Hypothyroid vs. Hyperthyroid

Your treatment path depends entirely on which direction your thyroid has gone. The two conditions are not just opposites on a dial; they carry different risks, different medications, and different monitoring schedules.

Hypothyroidism: When Your Thyroid Makes Too Little

Symptoms include fatigue, weight gain, cold intolerance, constipation, hair loss, brain fog, heavy periods, and depression. TSH rises when your pituitary is signaling the thyroid to work harder.

American Thyroid Association guidelines define overt hypothyroidism as a TSH above the upper limit of the reference range (typically 4.5-5.0 mIU/L depending on the lab) with a low free T4. Subclinical hypothyroidism is a raised TSH with a normal free T4. Deciding whether to treat subclinical hypothyroidism depends on symptom burden, antibody status, TSH level, and, very significantly, pregnancy status.

Hyperthyroidism: When Your Thyroid Makes Too Much

The most common cause is Graves' disease, another autoimmune condition with a strong female predominance. Symptoms include weight loss despite normal or increased appetite, palpitations, heat intolerance, anxiety, tremor, irregular periods, and sometimes eye changes (Graves' ophthalmopathy).

A suppressed TSH (below 0.4 mIU/L) with elevated free T4 or free T3 confirms overt hyperthyroidism.

The Full Menu of Thyroid Treatments

Below is a structured view of every treatment category in current use, organized by condition. Evidence grades follow the American Thyroid Association rating system.

Treatments for Hypothyroidism

Levothyroxine (Synthetic T4): The Standard of Care

Levothyroxine is the first-line treatment for hypothyroidism, supported by decades of evidence and endorsed by ACOG, the American Thyroid Association, and The Endocrine Society. It replaces T4, which your body converts to the active T3 in peripheral tissues.

Typical starting doses:

• Non-pregnant adults: approximately 1.6 mcg/kg of body weight per day for overt hypothyroidism; lower doses (25-50 mcg) used when starting in older adults or those with cardiac disease
• Pregnancy: doses often need to increase by 25-30% as soon as pregnancy is confirmed to meet fetal demand in the first trimester

Brand names in the US include Synthroid, Levoxyl, Tirosint, and Unithroid. Generic and brand formulations are not automatically interchangeable; consistent use of one formulation matters for stable TSH control.

How to take it correctly. Levothyroxine is taken on an empty stomach, 30-60 minutes before food, and separated from calcium supplements, iron, and antacids by at least 4 hours because these block absorption. One crossover study found that bedtime dosing improved TSH control in patients who struggled with morning fasting.

Combination T4/T3 Therapy: Liothyronine Added to Levothyroxine

Some women on adequate levothyroxine still report persistent fatigue, weight difficulty, and brain fog despite a normal TSH. Adding synthetic T3 (liothyronine, sold as Cytomel) addresses this for a subset of patients.

A 2019 randomized trial published in The Lancet Diabetes and Endocrinology found that approximately 25% of hypothyroid patients preferred combination therapy over levothyroxine alone on quality-of-life measures. The trial did not show a population-wide benefit, but did identify that patients with the DIO2 polymorphism may convert T4 to T3 less efficiently and are more likely to benefit.

Caution applies: T3 has a shorter half-life, can cause more cardiac side effects at higher doses, and requires more careful monitoring. It is generally avoided as monotherapy.

Desiccated Thyroid Extract (DTE): Armour Thyroid, NP Thyroid

Desiccated thyroid extract is derived from porcine thyroid gland and contains both T4 and T3 in a fixed ratio. Some patients request it by name after reading patient advocacy content online.

The clinical evidence for DTE over levothyroxine is not strong. A 2013 randomized crossover trial in the Journal of Clinical Endocrinology and Metabolism found that about 49% of patients preferred DTE and that it was associated with modest weight loss, but overall quality of life improvement was not statistically significant on the primary outcome. The fixed T4:T3 ratio (approximately 4:1) may not match individual needs, and the T3 content can cause fluctuating T3 levels throughout the day.

DTE is a reasonable option for patients who have tried and failed adequate levothyroxine therapy, ideally under specialist supervision.

Treatments for Hyperthyroidism

Antithyroid Drugs: Methimazole and Propylthiouracil (PTU)

Antithyroid drugs block thyroid hormone synthesis. Methimazole is preferred over PTU in non-pregnant adults because it has a longer half-life (allowing once-daily dosing), better safety profile, and faster biochemical response. Starting doses range from 5 to 30 mg daily depending on severity.

PTU is preferred in the first trimester of pregnancy because methimazole carries a small but real risk of specific birth defects (aplasia cutis, choanal atresia, esophageal atresia). After the first trimester, guidelines recommend switching back to methimazole due to PTU's risk of serious liver toxicity. This mid-pregnancy drug switch requires close monitoring.

Both drugs carry a rare but serious risk of agranulocytosis (a dangerous drop in white blood cells). Women on antithyroid drugs should seek immediate evaluation for any fever or sore throat.

Radioactive Iodine (RAI): Iodine-131

RAI is a definitive treatment that destroys most or all of the thyroid tissue. It is administered as a capsule or liquid, is generally well tolerated, and results in permanent hypothyroidism in the majority of treated patients, who then require lifelong levothyroxine.

RAI is absolutely contraindicated in pregnancy and breastfeeding. The NRC and FDA require a negative pregnancy test before RAI treatment. Reliable contraception is required for at least 6 months after RAI before attempting conception. Women who are breastfeeding should stop breastfeeding before treatment and should not resume breastfeeding from the treated breast after RAI.

RAI is also generally deferred in women with moderate to severe Graves' ophthalmopathy because it may worsen eye disease.

Thyroid Surgery (Thyroidectomy)

Surgical removal of part or all of the thyroid is indicated when a thyroid nodule is suspicious or confirmed malignant, when the gland is very large and causing compressive symptoms, when RAI is contraindicated (including in active pregnancy for refractory Graves' disease), or when a patient prefers surgery over lifelong medical management.

Total thyroidectomy results in permanent hypothyroidism requiring lifelong levothyroxine. Hemithyroidectomy (lobectomy) may preserve enough function that medication is not always required, though approximately 22% of patients after lobectomy develop hypothyroidism within 5 years.

Potential complications include damage to the parathyroid glands (causing hypocalcemia) and injury to the recurrent laryngeal nerve (causing voice changes). These risks are minimized at high-volume thyroid surgery centers.

Thyroid Treatment Comparison Table

| Treatment | Best For | Evidence Grade | Pregnancy Safe? | Key Consideration | |---|---|---|---|---| | Levothyroxine | Hypothyroidism, all stages | Strong | Yes, dose must increase | Take on empty stomach; consistent formulation | | Levothyroxine + Liothyronine | Persistent symptoms on T4 alone | Moderate | Liothyronine avoided in pregnancy | DIO2 polymorphism may predict response | | Desiccated Thyroid Extract | Patient preference, failed T4 alone | Weak/Moderate | Limited data; generally avoided | Fixed T4:T3 ratio; variable lot-to-lot potency | | Methimazole | Hyperthyroidism (non-pregnant) | Strong | Avoid in 1st trimester | Risk of agranulocytosis; monitor CBC with fever | | PTU | Hyperthyroidism in 1st trimester | Strong (in pregnancy) | 1st trimester only | Liver toxicity risk limits long-term use | | Radioactive Iodine | Definitive Graves' Rx, toxic nodules | Strong | Contraindicated | 6-month contraception required post-treatment | | Thyroidectomy | Cancer, large goiter, RAI failure | Strong | Possible in 2nd trimester | Permanent hypothyroidism likely |

Thyroid Treatment Across Your Life Stages

Reproductive Years (Ages 18-40)

Thyroid disorders frequently surface during the reproductive years, often presenting first as menstrual irregularity or difficulty conceiving. Hypothyroidism can suppress ovulation and raise prolactin levels, mimicking a pituitary problem. The ASRM Practice Committee recommends TSH testing as part of a standard infertility workup because normalizing TSH can restore ovulatory cycles without further intervention.

A TSH target of <2.5 mIU/L is generally recommended before attempting conception, though the 2017 American Thyroid Association guidelines note that the evidence for treating subclinical hypothyroidism to improve fertility outcomes is still evolving.

Women with PCOS have a higher prevalence of Hashimoto's thyroiditis, estimated at 17-22%, compared with approximately 8% in the general female population. Thyroid antibody testing is reasonable in any woman diagnosed with PCOS, particularly if she has menstrual irregularity beyond what PCOS alone explains.

Pregnancy and Postpartum

This is the life stage where thyroid management is most urgent and has the highest stakes.

Untreated overt hypothyroidism in pregnancy is associated with:

• Miscarriage and preterm birth
• Placental abruption
• Impaired fetal neurodevelopmental outcomes, including lower IQ scores in offspring

A landmark study by Haddow et al. (1999) in the New England Journal of Medicine found that children born to women with untreated hypothyroidism scored 7 points lower on IQ tests at age 7 compared to controls.

Levothyroxine dose requirements rise as early as weeks 4-6 of pregnancy because estrogen surges increase TBG, the placenta degrades T4, and the fetus cannot produce its own thyroid hormone until the second trimester. Women with known hypothyroidism should increase their levothyroxine dose by taking two extra doses per week as soon as pregnancy is confirmed, and recheck TSH within 4 weeks.

Postpartum thyroiditis is often overlooked. It typically presents as a hyperthyroid phase (weeks 1-6 postpartum) followed by a hypothyroid phase (months 4-8 postpartum). Most women recover full thyroid function within 12 months, but approximately 20-40% develop permanent hypothyroidism within 5-10 years. Any woman experiencing unexplained depression, fatigue, or heart palpitations in the postpartum year deserves a TSH check.

Breastfeeding and medication safety:

• Levothyroxine passes into breast milk only in tiny amounts and is considered safe for breastfeeding infants.
• Methimazole passes into breast milk. For women with hyperthyroidism who wish to breastfeed, PTU was historically preferred, though recent evidence suggests low-dose methimazole (up to 20 mg/day) is acceptable if thyroid function in the infant is monitored.
• RAI is absolutely contraindicated while breastfeeding.

Perimenopause (Ages 40-52)

This is the life stage with the most diagnostic overlap. Hot flashes, sleep disruption, weight changes, brain fog, mood shifts, and fatigue are symptoms of both perimenopause and thyroid dysfunction. The Menopause Society (formerly NAMS) recommends TSH testing when symptoms are ambiguous, because the two conditions can coexist and each requires its own treatment.

Menopausal hormone therapy (MHT) containing oral estrogen raises TBG, which can lower free T4 bioavailability and may require an increase in levothyroxine dose. Transdermal estrogen has less effect on TBG than oral estrogen, a practical consideration when prescribing for women already on thyroid replacement.

Postmenopause

In postmenopause, the primary thyroid concern shifts toward avoiding over-treatment. Excess levothyroxine (a suppressed TSH) accelerates bone loss and increases the risk of atrial fibrillation. A TSH kept below 0.1 mIU/L for more than 10 years is associated with a 4-fold increase in atrial fibrillation risk in women over 60. Target TSH for most postmenopausal women is 1.0-3.0 mIU/L; dose reductions are often needed as weight and estrogen levels decline.

Who Is Thyroid Treatment Right For, and Who Should Be Cautious?

Clear Indications

• Overt hypothyroidism (elevated TSH, low free T4): treatment is universally recommended
• Overt hyperthyroidism (suppressed TSH, elevated free T4/T3): treatment is required to prevent cardiac and bone complications
• Hypothyroidism in pregnancy: treat immediately
• Thyroid cancer: surgery plus TSH suppression therapy

Where the Evidence Is Less Clear

• Subclinical hypothyroidism (TSH 4.5-10 mIU/L, normal free T4) in non-pregnant women: The TRUST trial (2017) published in JAMA found no quality-of-life benefit from treating subclinical hypothyroidism in adults over 65. Treatment decisions in this group should weigh symptom burden, antibody positivity, cardiovascular risk, and reproductive plans.
• Thyroid antibodies with normal TSH: not an indication for levothyroxine outside of pregnancy, though some data from trials like TABLET suggest no miscarriage benefit from levothyroxine in euthyroid antibody-positive women.

Relative Cautions

• Significant cardiac disease: start thyroid replacement at low doses (12.5-25 mcg) and titrate slowly
• Women on warfarin: levothyroxine can potentiate anticoagulant effects; INR monitoring is required after dose changes
• Older postmenopausal women with osteoporosis: avoid TSH suppression; target the upper half of the reference range

Monitoring: What Labs You Need and When

Consistent monitoring is what separates adequate thyroid management from excellent thyroid management.

Standard Schedule

• New diagnosis or dose change: recheck TSH 4-6 weeks after the change
• Stable on levothyroxine: TSH every 6-12 months
• Pregnancy: TSH every 4 weeks through 20 weeks gestation, then once at 24-28 weeks
• Graves' disease on antithyroid drugs: TSH and free T4 every 4-6 weeks initially, then every 3 months once stable
• After RAI: TSH at 6 weeks, 3 months, then annually once stable on replacement

Which Labs Actually Matter

TSH is the primary monitoring tool for both conditions. Free T4 is added when TSH is abnormal or when evaluating during pregnancy. Free T3 is used when T3-containing therapy is prescribed or when symptoms suggest T3 excess. Thyroid antibodies (TPO-Ab, TG-Ab) are measured at diagnosis to confirm autoimmune etiology; they do not need repeated routine testing once the diagnosis is established.

Bone density (DXA) is appropriate for postmenopausal women who have had prolonged TSH suppression.

What Your Doctor Should Tell You But Might Not

"The single most common reason women feel undertreated on levothyroxine is absorption failure, not dose failure," says Sarah Chen, WHNP, clinical lead at WomanRx. "Before adjusting dose, we review every supplement, medication, and timing habit because a 600 mg calcium tablet taken with levothyroxine can reduce absorption by up to 40%."

This matters because absorption variables, including coffee, dietary fiber, proton pump inhibitors, and soy-containing foods, can all shift levothyroxine availability. A pharmacokinetic study in Thyroid journal confirmed that coffee taken within one hour of levothyroxine reduces absorption significantly, a finding many women are never told at first prescription.

FAQs